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INTRODUCTION
Chronic graft-versus-host disease (GVHD) remains a
major complication of allogeneic bone marrow transplanta-
tion and affects 25% to 50% of long-term survivors, with a
case mortality rate of 20% to 40% [1,2]. Matching the dura-
tion or intensity of immunosuppression with the patient’s
likelihood of developing chronic GVHD might lead to
increased patient survival. Increasing the immunosuppres-
sion for high-risk patients theoretically could decrease the
risk of chronic GVHD, whereas decreasing or discontinuing
the immunosuppression for low-risk patients might lead to
better patient survival because of fewer side effects from
immunosuppression, including infections. An analysis of
pretransplantation characteristics and of the early posttrans-
plantation course might allow physicians to identify patients
at low versus high risk for chronic GVHD.
To this aim, we retrospectively analyzed data from
489 patients, all of whom had received methotrexate (MTX)
and cyclosporine (CSP) to prevent GVHD. Given that earlier
reports had identiﬁed acute GVHD as a major risk factor for
chronic GVHD [3-6], patients with grades II through IV acute
GVHD were excluded from the current analysis [4]. Thus, the
focus of the current study was on de novo chronic GVHD.
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ABSTRACT
A retrospective study was performed to determine risk factors for the development of de novo chronic graft-versus-
host disease (GVHD) in patients given marrow grafts from HLA-identical sibling donors (85%), HLA-nonidentical
family members (3%), or HLA-matched unrelated donors (12%) and for postgrafting immunosuppression with
methotrexate and cyclosporine. We also examined the impact of chronic GVHD on survival and identified patients at
low risk for chronic GVHD in whom immunosuppression might be stopped safely early after transplantation. Among
489 patients with either grade 0 or I acute GVHD, 33% developed chronic GVHD. Overall survival was 70%, and
relapse-free survival was 63% at 8 years. Risk factors for chronic GVHD were found to include donor buffy coat infu-
sions among patients given transplants for aplastic anemia (relative risk [RR] = 2.9, P = .05), patient–donor sex/parity
combination (likelihood ratio test, P < .001), grade I acute GVHD (RR = 1.6, P = .003), and active cytomegalovirus
infection (RR = 1.5, P = .05) before day 60. Among 45 patients aged <19 years who had male donors, only 1 developed
chronic GVHD. This group had an overall survival rate of 65% and a relapse-free survival rate of 54% at 8 years post-
transplantation—a result not better than that among the entire cohort. The lack of improvement in survival in the
low-risk group was related to a high rate of relapse of the underlying diseases. Therefore, the development of de
novo chronic GVHD does not have a negative impact on patient survival; the adverse effect from increased transplan-
tation-related complications is offset by a lower relapse rate, the result of an allogeneic graft-versus-tumor effect.
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MATERIALS AND METHODS
Patients
Data from 489 patients who received unmodiﬁed allo-
geneic marrow grafts and were given MTX/CSP between
December 1981 and July 1995 in Seattle were retrospectively
analyzed. Patients had either grade 0 or transient grade I
acute GVHD. Chronic GVHD was deﬁned as any GVHD
occurring after day 60 that required systemic immunosup-
pression. Only patients without cytogenetic or morphological
relapse or graft rejection before day 60 were included in the
study. Patients were censored at the time of relapse. Follow-
up among surviving patients ranged from 0.6 to 14.1 years
(median, 5.7 years). Of the 489 patients, 23 were excluded
from the multivariable analyses because of chart deﬁciencies.
Table 1 describes the cohort of patients studied. The
cohort contained a small percentage of patients with HLA-
matched unrelated (12%) or HLA-mismatched related
donors (3%), but most (85%) had HLA-matched sibling
donors. Patients who underwent transplantations had a vari-
ety of malignant diseases, including acute leukemias, and non-
malignant diseases such as aplastic anemia. Of the patients,
86% had hematologic malignancies. The ages of patients
ranged from 6 months to 60 years. For conditioning, most
patients received busulfan and cyclophosphamide (Cy) (27%),
Cy and total body irradiation (55%), or Cy alone (7%).
Table 1. Characteristics of 489 Patients Who Underwent Transplantation
and of Their Associated Treatments*
n† 489
Patient age, y
Median 32
0-20 100 (20)
>20 389 (80)
Patient sex
Male 262 (54)
Female 227 (46)
Donor age, y
Median 32
0-20 95 (19)
>20 394 (81)
Buffy coat infusion
No 478 (98)
Yes 11 (2)
Donor sex/parity → patient sex
Male → male 149 (30)
Male → female 107 (22)
Nonparous female → male 61 (12)
Nonparous female → female 54 (11)
Parous female → female 66 (14)
Parous female → male 52 (11)
Diagnosis/disease status‡
Advanced malignancy 107 (22)
Nonadvanced malignancy 311 (64)
Nonmalignant disease 69 (14)
Grade I acute GVHD by day 60
No 358 (74)
Yes 131 (26)
Day of onset of grade I acute GVHD
1-20 61 (47)
21-40 51 (40)
41-60 17 (13)
Transplantation year
1981-1987 128 (26)
1988-1991 230 (47)
1991-1995 131 (27)
Patient HSV serological status
Negative 170 (35)
Positive 301 (65)
Patient CMV serological status
Negative 233 (48)
Positive 254 (52)
Donor CMV serological status
Negative 276 (57)
Positive 211 (43)
Corticosteroid usage
Days 1-14
No 454 (89)
Yes 35 (7)
Days 15-60
No 433 (89)
Yes 56 (11)
MTX, % of protocol dose
First quintile: <90% 97
Second quintile: 90% to 98% 98
Third quintile: 98% to 99.5% 98
Fourth quintile: 99.5% to 101% 98
Fifth quintile: ≥101% 98
CSP weeks 1-2, % of protocol dose
First quintile: <90% 96
Second quintile: 90% to 96% 96
Third quintile: 96% to 99% 96
Fourth quintile: 99% to 102% 96
Fifth quintile: ≥102% 97
(Continued)
Table 1 cont.
CSP weeks 3-5, % of protocol dose
First quintile: <71% 96
Second quintile: 71% to 90% 96
Third quintile: 90% to 98% 96
Fourth quintile: 98% to 115% 96
Fifth quintile: ≥115% 97
Bacterial infection before day 60
No 112 (23)
Yes 377 (77)
CMV infection before day 60
No 410 (84)
Yes 78 (16)
Any viral infection before day 60
No 324 (66)
Yes 164 (34)
Fungal infection before day 60
No 259 (53)
Yes 230 (47)
*Data are n or n (%). GVHD indicates graft-versus-host disease;
HSV, herpes simplex virus; CMV, cytomegalovirus; MTX, methotrex-
ate; CSP, cyclosporine.
†Totals may not equal 489 for all categories because some informa-
tion was not available for 20 patients.
‡Advanced malignancy includes chronic myelogenous leukemia
(CML) in accelerated phase or blast crisis; acute myelogenous
leukemia, multiple myeloma, acute lymphocytic leukemia, chronic
myelomonocytic leukemia, and lymphoma in relapse; and refractory
anemia with excess blasts or refractory anemia with excess blasts in
transformation. CML in chronic phase, refractory anemia, refractory
anemia with ringed sideroblasts, or malignancies in remission were
considered nonadvanced malignancies. Nonmalignant diseases include
aplastic anemia and congenital immunodeﬁciencies.
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GVHD Prophylaxis
The MTX regimen has been described [7]. CSP treat-
ment was begun intravenously 1 day before the marrow infu-
sion until patients could take the oral form. Frequent dose
adjustments were made based on blood CSP and serum crea-
tinine levels [7]. After day 50, CSP dosage was decreased by
5% per week and stopped at 6 months after transplantation
in the absence of chronic GVHD development.
Chronic GVHD Assessment
Extensive chronic GVHD was deﬁned by clinical signs
or symptoms involving 1 or more major organ systems and
1 or more biopsies showing histopathological evidence of
GVHD [8]. All patients with chronic GVHD had histologi-
cal conﬁrmation by biopsy of at least 1 organ system. Skin
involvement was deﬁned as erthyema, dryness, itching, pig-
ment changes, mottling, plaques, papules, exfoliation, and,
in later stages, induration and contractures. A skin biopsy
showed changes consistent with chronic GVHD that
included hyperkeratosis and, later, atrophic keratinocytes
[9]. A lip biopsy, if obtained, showed findings consistent
with chronic GVHD including lymphoplasmocytic infil-
trates and fibrous destruction of the salivary glands [10].
Liver involvement included elevated liver function tests
(predominantly alkaline phosphatase). In the absence of
GVHD in other organs, a liver biopsy was required for
diagnosis [11]. Eye involvement was deﬁned as a Schirmer
test result with a mean value in both eyes of ≤5 mm at
5 minutes or of <10 mm with signs of keratitis, conjunctivi-
tis, or symptoms of ocular sicca with pain, burning, blurring,
dryness, grittiness, or photophobia [12]. Gastrointestinal
involvement included symptoms of dysphagia or odynopha-
gia with evidence of esophageal stenosis or anorexia, nausea,
vomiting, weight loss, or diarrhea with endoscopic confir-
mation [13]. Lung involvement was defined as a new
obstructive defect with changes on spirometry resulting in a
forced expiratory volume in 1 second (FEV1)/forced vital
capacity of 70% or an FEV1 of <80% or a decrease of >30%
in previous pulmonary function tests not due to infections
or other etiologies [14]. A biopsy showed pathological
changes consistent with bronchiolitis obliterans [15]. Vagi-
nal GVHD was deﬁned as dryness of the vagina with stric-
ture formation or stenosis [16]. A biopsy was necessary to
confirm GVHD involving this organ system. Muscle
involvement was defined as proximal muscle weakness
sometimes with cramping, with increased creatinine phos-
phokinase, aldolase, and electromyogram ﬁndings consistent
with myositis [17]. If the muscle was the only organ
involved, a biopsy was required to confirm the diagnosis.
Patients whose disease relapsed before diagnosis of chronic
GVHD were censored at the time of relapse because of
attempts to induce graft-versus-leukemia effects by rapidly
tapering immunosuppression.
Infections
Bacterial and fungal infections were considered estab-
lished only when positive cultures arose from “sterile” sites
that normally did not contain bacteria or fungi such as sinus,
lung, liver, cerebrospinal fluid, pleural fluid, eye, blood,
bone marrow, spleen, brain, and urinary tract. Other sites,
such as mouth, catheter exit sites, skin, and gastrointestinal
tract, were considered nonsterile. Viral infections included
cytomegalovirus (CMV), herpes simplex virus (HSV), vari-
cella zoster virus, and a small number of other viruses
including respiratory syncytial virus and adenovirus. Viral
infections were defined as any detection of the virus by
culture, shell vial, or direct fluorescent antibody (DFA)
regardless of symptoms before day 60 after transplantation.
Posttransplantation Events
Patient demographic characteristics and posttransplanta-
tion events occurring between day 0 (the day of marrow infu-
sion) and day 60 that could influence the development of
chronic GVHD are shown in Table 1. A total of 26% of
patients had grade I acute GVHD, which developed in most
(87%) before day 40. Only 11% of patients received signiﬁ-
cant doses of corticosteroids (≥0.9 mg/kg prednisone) for a
variety of reasons, including continued treatment of their
underlying malignancy, idiopathic interstitial pneumonitis,
severe mucositis, and asthma. Most patients (>80%) received
between 90% and 110% of the protocol-recommended
dosages of MTX and CSP. Only 3% of the patients had CSP
withheld longer than 3 days because of side effects such as
high CSP blood levels, nephrotoxicity, and neurotoxicity. Of
the patients, 77% had bacterial infections. Fungal infections
were found in 47% of patients, but they were mostly localized
candidal infections or colonization, for example, of the gas-
trointestinal tract, and only 3% of patients had fungal infec-
tions in sterile sites. Most viral infections were due to HSV,
but 16% of patients developed CMV infections, as deﬁned by
culture or DFA of blood or other sites, including lung or gas-
trointestinal tract tissue.
Statistical Methods
The primary outcome of interest in this study was
whether extensive clinical chronic GVHD developed. Uni-
variate (Table 2) and multivariate Cox regression analyses
(Tables 3 and 4) were used to evaluate the strength of associ-
ation between this outcome and the potential risk factors.
Risk factors analyzed for the development of chronic GVHD
included standard demographic characteristics, percentage of
protocol doses of CSP and MTX, and infections in the ﬁrst
60 days after transplantation. The number of covariates
examined was large relative to the size of the cohort. The
large number of covariates had 2 major implications. First,
results should be interpreted with caution because the likeli-
hood of ﬁnding 1 or more spurious “risk factors” increased as
more covariates were analyzed. Thus, we considered P values
of <.005 to represent strong evidence of an association with
chronic GVHD development and P values of .005 to .05 to
represent weak evidence. Analyses were performed in
December of 1998.
The second consequence of the wide breadth of our
study was that we could not perform multivariate Cox
regression using all covariates simultaneously because of
mathematical stability considerations. Covariates fell into
2 classes: those that were evaluative before or at the time of
bone marrow transplantation and those that could not be
deﬁned until the patient reached approximately day 60 after
transplantation (for example, compliance to protocol
dosages of CSP and MTX and presence of CMV infection).
Because of this ﬁnding, we chose to perform the analysis in
J.L. Wagner et al.
636
2 stages. First, all pretransplantation factors were included in
a single Cox regression model to see which showed associa-
tions with chronic GVHD that could not be attributed to
other patient, donor, or transplantation regimen characteris-
tics. Second, a reduced version of that pretransplantation
model was chosen through forward stepwise regression. The
estimates of relative risks and P values reported in Table 4 for
each posttransplantation covariate came from separate estima-
tions of the reduced pretransplantation model with 1 addi-
tional covariate added. We did not have enough patients in
our cohort to assess all posttransplantation covariates simul-
taneously, even using the reduced pretransplantation model.
For drug doses, we chose to use quintiles (ie, the 20% of
patients who received the smallest fraction of their scheduled
MTX would fall into the ﬁrst quintile; the next 20% would
fall into the second quintile, etc.) to be able to accommodate
a U-shaped relationship between drug dosage and chronic
GVHD. This procedure seemed desirable because a devia-
tion from the protocol schedule in either direction (too little
or too much drug) could be a marker for adverse events.
Next, a cohort of patients who were at low risk for chronic
GVHD development was identiﬁed, and each patient’s overall
survival rate was compared with that of the entire cohort as
well as with a group of patients with chronic GVHD who did
not respond to the initial immunosuppressive regimen.
Finally, the causes of death in various subgroups were
analyzed. The cause of death was listed as relapse if the
patient had relapsed disease even if the immediate cause of
death was something other than GVHD (for example,
complications from a second transplantation or sepsis
after posttransplantation chemotherapy). For cases in
which the patient had GVHD that contributed to death
but had infections or other conditions that were the
immediate cause of death, both causes were listed.
RESULTS
Overall Chronic GVHD Incidence and Survival
Of the patients, 33% developed chronic GVHD with an
overall survival rate of 71% and a relapse-free survival rate of
62% at 5 years (Figure). Of the 489 patients, 134 died, and 89
(66%) of the deaths were from relapse of disease and 24
(18%) were from complications associated with chronic
GVHD. Overall, 18% of all patients died from disease
relapse and 5% from chronic GVHD.
Univariate Analyses
Table 2 shows the univariate analysis of risk factors for
the development of chronic GVHD. Factors that provided
either strong or weak associations (P ≤ .05) with the devel-
opment of chronic GVHD included greater donor age,
greater patient age, male patients with parous female
donors, year of transplantation, grade I acute GVHD, use of
corticosteroids (≥0.9 mg/kg prednisone) after day 14, and
conditioning regimen (data not shown). Factors that did not
increase the risk of chronic GVHD included donor and
patient CMV serostatus, use of laminar airflow rooms,
patient HSV serostatus, degree of HLA match, and day of
onset of acute GVHD grade I (data not shown).
In the univariate analyses, none of the infections occur-
ring before day 60 were shown to confer a statistically
significant increase in the risk of GVHD. When bacterial
culture data were broken down by sites of infection or types
of infectious organisms, no additional associations were
found. Additionally, there was no relationship between the
development of bacteremias and the development of chronic
GVHD. There was also no relationship between certain
types of infections, eg, bacteremias with gram-negative
organisms or gastrointestinal tract colonization with anaero-
bic organisms, and the development of chronic GVHD
(data not shown). However, the higher the number of posi-
tive cultures for bacterial infections from any sterile site, the
higher the risk of chronic GVHD (relative risk [RR] = 2.07,
P = .006) (data not shown). Results suggested that there was
no relationship between chronic GVHD and a speciﬁc bac-
terial organism that caused an infection or the site of infec-
tion, but patients with multiple bacterial infections were at a
higher risk for chronic GVHD.
Multivariate Analyses
For variables determined before transplantation, only
use of unirradiated buffy coat infusions formerly given to
patients with aplastic anemia to prevent graft rejection [18]
Kaplan-Meier overall survival, disease-free survival, relapse rate, and chronic graft-versus-host disease (GVHD) incidence for the entire cohort.
Chronic GVHD: Risk Factors and Survival
637B B & M T
(RR = 2.9, P = .05) and donor sex/parity combination with
the highest risk among male patients with parous female
donors (RR = 3.0; likelihood ratio test, P < .001) had signiﬁ-
cant effects not attributable to the other factors (Table 3).
Interestingly, neither patient nor donor ages were statisti-
cally associated with increased incidence of de novo chronic
GVHD. Other risk factors in the univariate analysis that did
not remain signiﬁcant in the multivariate analysis included
conditioning regimen and year of transplantation.
The next stage of the analysis was to assess whether any
of the variables deﬁned during the ﬁrst 60 days after trans-
plantation showed an impact on the risk of chronic GVHD
after controlling for pretransplantation characteristics
(Table 4). A history of grade I acute GVHD (RR = 1.6, P =
.003) and, less strongly, the presence of CMV infection of
any site by culture or DFA (RR = 1.5, P = .05) were signiﬁ-
cantly associated with increased risks of chronic GVHD.
The number of bacterial infections (data not shown) was no
longer associated with chronic GVHD development.
Survival Among Patients With Low Risk for Chronic
GVHD
Next we identified a group of patients who were at a
low risk of chronic GVHD. These patients were <19 years
of age with male donors. Only 1 of these 45 patients devel-
oped chronic GVHD. Their overall survival rate was 62%
at 5 years, and their relapse-free survival rate was 59% at
5 years (compared with 71% and 62%, respectively, for the
entire cohort). The major difference between the low-risk
group and the rest of the cohort, other than the decreased
incidence of chronic GVHD, was the increased relapse
rate. Table 5 shows the causes of death for patients in the
low-risk group compared with the other patients. The
major cause of death in the low-risk group was disease relapse
in 13 of the 15 deaths (84%) compared with 76 of 119 deaths
(64%) in the rest of the cohort.
Table 2. Univariate Analysis of Factors Associated With De Novo Chronic
GVHD Development (n = 489)*
Relative
Risk Factors Risk P
Patient age ≤20 versus >20 years 2.54 <.0001†
Donor age ≤20 versus >20 years 2.82 <.0001
Buffy coat infusion versus no buffy coat infusion 1.80 .13
Transplantation year
1981-1987 0.54
1988-1991 0.67 .01†
1991-1995 1.00‡
MTX received
First quintile 1.07
Second quintile 0.91
Third quintile 1.00‡ .97†
Fourth quintile 0.97
Fifth quintile 1.04
CSP received weeks 1-2
First quintile 1.66
Second quintile 1.44
Third quintile 1.00‡ .03†
Fourth quintile 0.97
Fifth quintile 1.04
CSP received weeks 3-5
First quintile 1.11
Second quintile 1.13
Third quintile 1.00‡ .06†
Fourth quintile 0.97
Fifth quintile 1.04
Acute GVHD grade I versus grade 0 1.65 .003
Corticosteroids received days 1-14 1.38 .24
Corticosteroids received after day 14 1.58 .05
Bacterial infection before day 60 1.40 .10
CMV infection before day 60 1.26 .25
HSV infection before day 60 0.86 .51
Fungal infection before day 60 0.91 .54
Disease type
Advanced malignancy 1.4
Nonadvanced malignancy 1.0‡ .08†
Nonmalignant disease 0.8
Donor sex/parity → patient sex
Male → male 1.00†
Male → female 0.73 <.0001†
Nonparous female → female 0.51
Nonparous female → male 1.26
Parous female → female 1.35
Parous female → male 2.76
*GVHD indicates graft-versus-host disease; MTX, methotrexate;
CSP, cyclosporine; CMV, cytomegalovirus; HSV, herpes simplex virus.
†Likelihood ratio test P value for the signiﬁcance of the whole set
of levels for this factor.
‡For factors with >2 levels, 1.00 indicates the level that serves as the
reference group when computing the relative risks for each of the other
levels of that factor.
Table 3. Basic Multivariate Cox Model Examining Factors Associated With
Chronic GVHD (n = 466)*
Factors Relative Risk P
Donor age >20 versus ≤20 years 1.8 .08
Patient age >20 versus ≤20 years 1.8 .12
Buffy coat infusion 2.9 .05
Donor HLA type
Matched sibling 1.0†
Mismatched sibling donor 1.0
Other relative 2.0 .36†
Unrelated 1.2
Diagnosis/disease status‡
Advanced malignancy 1.3
Nonadvanced malignancy 1.0† .52†
Nonmalignant disease 1.1
Transplantation year
1981-1987 0.69
1988-1991 0.77 .36†
1992-1995 1.0†
Donor sex/parity → patient sex
Male → male 1.0†
Male → female 0.6 <.001†
Nonparous female → female 0.7
Nonparous female → male 1.9
Parous female → female 1.2
Parous female → male 3.0
*GVHD indicates graft-versus-host disease.
†Likelihood ratio test P value.
‡Diagnosis/disease status as deﬁned in Table 1.
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Survival Among Patients With Therapy-Refractory
Chronic GVHD
Among the 161 patients who developed chronic GVHD,
we identiﬁed 58 who had refractory chronic GVHD that did
not initially respond to increased immunosuppression. These
refractory patients tended to be slightly older than the over-
all cohort (35 versus 32 years) with slightly older donors (35
versus 32 years). The group included mainly patients with
CML (39 of 58). Furthermore, these patients were more
likely to have parous female donors (53% versus 25%) com-
pared with the entire study cohort. Among refractory
patients, the 5-year overall survival rate was similar to that of
the entire study cohort (70% versus 71%). Patients with
refractory chronic GHVD had a better overall 5-year sur-
vival rate than that of the low-risk group (70% versus 62%).
Among the 16 patients who died with refractory chronic
GVHD, only 4 (25%) had disease relapse, whereas the
remainder died of complications related to chronic GVHD.
DISCUSSION
The current study was aimed at deﬁning risk factors for
de novo chronic GVHD in patients given MTX/CSP for
GVHD prophylaxis and describing the impact of de novo
chronic GVHD on survival. Study results were used to
identify patients at low risk for chronic GVHD in whom
immunosuppression might be safely discontinued early and
in those at high risk for chronic GVHD who might beneﬁt
from extended immunosuppressive therapy. The study,
which identiﬁed 4 risk factors, included the use of buffy coat
infusions in patients with aplastic anemia, grafts from parous
female donors into male recipients, acute grade I GVHD,
and CMV infection before day 60.
Previous studies have shown that donor buffy coat infu-
sions increased the risk for chronic GVHD [3,19]. The studies
expressed the hypothesis that the increased incidence of
chronic GVHD was due to the large number of T cells
infused whose activities were contained by the early posttrans-
plantation immunosuppression, but when GVHD prophylaxis
was discontinued, resulted in chronic alloimmune reactions.
The association of grade I acute GVHD with chronic
GVHD has been noted in multiple studies [3,5,19]. It is
likely that both acute and chronic GVHD are caused by
alloreactive T cells present in the transplanted donor mar-
row, and, thus, risk factors for the development of both
complications might be similar. Whereas alloimmune reac-
tions leading to acute GVHD might be controlled by the
initial posttransplantation immunosuppressive therapy,
graft-host tolerance might not have been achieved in all
cases, and this might result in de novo chronic GVHD once
immunosuppression has been tapered or discontinued [20].
Current results suggested, although not strongly, that
early CMV infection had an association with chronic
GVHD. The reasons for this relationship were unclear. Pre-
vious studies had speculated that associations between CMV
seropositivity or infection and chronic GVHD [21,22] might
be related to donor lymphocyte exposure to CMV antigens
resulting in secretion of cytokines that triggered GVHD.
The parity of female donors and sex of the donor and
recipient were significant risk factors for de novo chronic
GVHD development, with the combination of the parous
female donor and male recipient having the highest risk for
GVHD development. In 1 study [23], the combination of
parous female donors and male recipients had the highest
risk of acute GVHD, and this finding was confirmed in 2
subsequent studies [5,24]. Parity likely increases the risk of
GVHD because of sensitization of the female donors against
polymorphic minor histocompatibility antigens in the recip-
ients via fortuitous exposure during pregnancy to paternal
antigens inherited by the child.
We were able to identify a group of patients in whom
postgrafting immunosuppression probably could be discontin-
ued earlier than the customary 180 days. Among 45 patients
<19 years of age who had male donors, only 1 (2%) developed
de novo chronic GVHD. Conversely, we were unable to iden-
tify a group of patients at very high risk for chronic GVHD.
Differences between the low-risk patients and the other
patients of the study cohort might explain the lack of survival
advantage in this group. The low-risk group had signiﬁcantly
more acute leukemia patients than the rest of the cohort (49%
versus 23%), and the low-risk group had more deaths by per-
centage due to relapse than the rest of the cohort. The reason
Table 4. Multivariate Cox Regressions for Posttransplantation Factors
Associated With Chronic GVHD (n = 466)*
Factors Relative Risk P
Acute GVHD grade I† 1.6 .003
Corticosteroid usage days 1-14 1.4 .22
Corticosteroid usage days 15-60 1.5 .06
Bacterial infection before day 60‡ 1.4 .11
CMV infection before day 60 1.5 .05
Any viral infection before day 60 1.2 .25
Fungal infection before day 60‡ 0.9 .65
HSV infection before day 60 0.8 .47
MTX dose received
First quintile 1.1
Second quintile 1.0
Third quintile 1.0 .93
Fourth quintile 0.9
Fifth quintile 1.1
CSP received weeks 1-2
First quintile 1.4
Second quintile 1.3
Third quintile 1.0 .29
Fourth quintile 0.9
Fifth quintile 1.4
CSP received weeks 3-5
First quintile 1.2
Second quintile 1.0
Third quintile 1.0 .26
Fourth quintile 1.5
Fifth quintile 0.9
*This model adjusts for pretransplantation factors listed in Table 3.
GVHD indicates graft-versus-host disease; CMV, cytomegalovirus;
HSV, herpes simplex virus; MTX, methotrexate; CSP, cyclosporine.
†For covariates listed below acute GVHD grade I, acute GVHD
was added to the basic Cox model.
‡Cultures showing only normal flora from nonsterile sites were
considered negative. Only specimens collected according to standard
patient care were considered in this analysis. Specimens collected for
special research projects were excluded.
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for the lack of survival advantage in the low-risk group could
be related both to the higher proportion of acute leukemia
patients and the lack of a graft-versus-leukemia effect.
Although the refractory GVHD group and the low-risk
group had similar survival rates, the 2 groups cannot be
compared directly because the chronic refractory GVHD
group selects for patients not in relapse who might survive
longer. Nevertheless, the data suggest that whereas the
development of chronic GVHD in the absence of signiﬁcant
acute GVHD perhaps adversely affects survival, the disad-
vantage is offset by lower relapse rates for patients with
malignant diseases. A subgroup of patients (those <19 years
of age with male donors) might beneﬁt from early cessation
of immunosuppression to induce a graft-versus-leukemia
effect and decrease the number of deaths from relapse.
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Table 5. Causes of Death for Patients in the Low-Risk Chronic GVHD
Group and Other Groups*
Low-Risk Chronic
GVHD Group All Others
n 15 119
Relapse 13 (87) 76 (64)
GVHD and infection 1 (7) 11 (9)
GVHD and noninfectious 0 12 (10) 
pulmonary disease
Noninfectious pulmonary disease 0 7 (6)
Infections 1 (7) 12 (10)
New malignancy 0 1 (1)
Data are n or n (%). Percentages may not add to 100% because of
rounding. GVHD indicates graft-versus-host disease.
